Product Overview
[Drug Name]
Trade Name: Ubilu
English Name: Pantoprazole Sodium Enteric-Coated Tablets
[Ingredients]
The main ingredient of this product is pantoprazole sodium.
[Properties]
This product is an enteric-coated tablet, which appears white or off-white after removing the coating.
[Indications]
It is indicated for active peptic ulcers (gastric and duodenal ulcers), reflux esophagitis, and Zollinger-Ellison syndrome.
[Dosage and Administration]
Oral administration: 40 mg (1 tablet) daily before meals in the morning. The treatment course for duodenal ulcers is usually 2-4 weeks, while the treatment course for gastric ulcers and reflux esophagitis is usually 4-6 weeks.
[Adverse Reactions]
Dizziness, insomnia, drowsiness, nausea, diarrhea and constipation, rash, and muscle pain may occur occasionally during clinical use.
[Contraindications]
This product is contraindicated in breastfeeding women and women within three months of pregnancy.
[Precautions]
1. High doses may cause arrhythmia, elevated transaminases, changes in renal function, and decreased granulocyte counts. 2. This product is an enteric-coated formulation. Do not chew when taking it. 3. When gastric ulcers are suspected, the possibility of cancer should be ruled out first. This is because treatment with this product may alleviate symptoms and thus delay diagnosis. 4. Efficacy and safety data for this product in children have not been established. 5. Use with caution in patients with hepatic and renal impairment.
[Special Population Use]
Precautions for Children: Efficacy and safety data for this product in children have not been established. This product is contraindicated in infants and young children.
Precautions for Pregnancy and Lactation: This product is contraindicated in breastfeeding women and women within three months of pregnancy.
Precautions for the Elderly: No dose adjustment is required.
[Drug Interactions]
Pantoprazole has minimal interactions with other drugs. Compared with omeprazole, it has less effect on the cytochrome P450 system and does not affect the duration of diazepam action. There are no significant interactions with oral contraceptives, digoxin, warfarin, phenytoin, or theophylline.
[Pharmacological Action]
This product specifically acts on gastric mucosal parietal cells, reducing the activity of H+-K+-ATPase in these cells, thereby inhibiting gastric acid secretion. Compared with omeprazole, this product has a weaker inhibitory effect on cytochrome P450 enzymes.
[Storage]
Store in a cool, dark place, sealed and protected from light.
[Strength]
40mg
[Packaging]
7 tablets/box
[Expiry Date]
24 months
[Approval Number]
National Medicine Standard No. H20059019
[Manufacturer]
Company Name: Hunan Warner Pharmaceutical Co., Ltd.
